Cross-Disorder Analysis of De Novo Mutations in Neuropsychiatric Disorders

Kuokuo Li1,2,3,4 • Zhenghuan Fang2 • Guihu Zhao1 • Bin Li1 • Chao Chen2 • Lu Xia2 • Lin Wang2 • Tengfei Luo2 • Xiaomeng Wang2 • Zheng Wang1 • Yi Zhang1 • Yi Jiang2 • Qian Pan2 • Zhengmiao Hu2,5 • Hui Guo2,5 • Beisha Tang1,5 • Chunyu Liu2,6 • Zhongsheng Sun7,8 • Kun Xia2,9,10 • Jinchen Li1,2,5

Accepted: 14 April 2021 / Published online: 10 May 2021
© The Author(s) 2021

Abstract
The clinical similarity among different neuropsychiatric disorders (NPDs) suggested a shared genetic basis. We catalogued 23,109 coding de novo mutations (DNMs) from 6511 patients with autism spectrum disorder (ASD), 4,293 undiagnosed developmental disorder (UDD), 933 epileptic encephalopathy (EE), 1022 intellectual disability (ID), 1094 schizophrenia (SCZ), and 3391 controls. We evaluated that putative functional DNMs contribute to 38.11%, 34.40%, 33.31%, 10.98% and 6.91% of patients with ID, EE, UDD, ASD and SCZ, respectively. Consistent with phenotype similarity and heterogeneity in different NPDs, they show different degree of genetic association. Cross-disorder analysis of DNMs prioritized 321 candidate genes (FDR < 0.05) and showed that genes shared in more disorders were more likely to exhibited specific expression pattern, functional pathway, genetic convergence, and genetic intolerance.

Keywords Neuropsychiatric disorder • De novo mutation • Candidate gene • Expression pattern • Functional network

Introduction
Neuropsychiatric disorders (NPDs) are a group of disorders with brain dysfunction, leading to abnormal in cognition, behavior, mood and communication. The influence of NPDs to international public health is acknowledged, especially due to their high clinical complexity (Craddock & Owen,
The similarity and heterogeneity among different types of NPDs such as autism spectrum disorder (ASD), epileptic encephalopathy (EE), intellectual disability (ID), and schizophrenia (SCZ), undiagnosed developmental disorder (UDD) promote clinicians and researchers studying them. These disorders tend to strike before adolescence, in particular ASD, EE, ID, and UDD onset during the time of infant and child (Forrest, Parnell, & Penzes, 2018). Their clinical phenotypes vary significantly among different patients from mild to severe impairment in many aspects of brain development and other organ system (Martin et al., 2018). NPDs are defined as distinct clinical classifications based on DSM-5 and ICD-11, whereas significant overlap of symptoms between different disorders (Moreno-De-Luca et al., 2013). For example, 20% of patients that meet the criteria of more than one disorder (Adam, 2013) and family history of one disorder increased the risk of another disorder (Sullivan et al., 2012). In addition, because of significant clinical similarity of ID and UDD, previous studies frequently combined individuals with these two disorders to explore genetic reasons (Coe et al., 2019; Satterstrom et al., 2020). Moreover, due to the dynamic nature of symptoms, patients often receive diagnoses of additional disorders, particular within the first year of the original diagnosis, and these pair comorbidities were bidirectional (Plana-Ripoll et al., 2019). All of these studies highlight the clinical similarity among NPDs, which implicated common etiological mechanisms.

Twins and adoption studies exhibited high heritability of NPDs, which provides the opportunity to understand their etiologies from genetic perspective (Polderman et al., 2015). The clinical similarity of NPDs might implicated by genetic. Recently, multiple studies employed whole-exome sequencing (WES) or whole-genome sequencing (WGS) to detect de novo mutations (DNMs) and successfully prioritized candidate genes with DNMs in ASD (An et al., 2018; Iossifov et al., 2014), UDD (Deciphering Developmental Disorders, 2017), EE (Epi et al., 2013), ID (Lelieveld et al., 2016), and SCZ (Fromer et al., 2014). Due to the strong functional effects of DNMs [16], some candidate genes have been established to be associated with specific clinical phenotypes, such as CHD8 (Bernier et al., 2014) with ASD, ID, sleep problem, macrocephaly; and gastrointestinal symptoms, and DYRK1A (van Bon et al., 2016) with ID, macrocephaly and febrile seizures infancy. Genotype–phenotype correlation analysis will strengthen the genetic evidence (Dong et al., 2014; Willsey et al., 2013); integration of DNMs that distributed in different publications was an effective method to increase sample size of patients carrying DNMs of specific disease gene (Li et al., 2016; Nguyen et al., 2017). In addition, consistent with SNP based genetic correlation, genes with DNMs also show of significant overlap between different classification of NPDs (Cross-Disorder Group of the Psychiatric Genomics, 2013; Schork et al., 2019). Moreover, genetic correlations among bipolar disorder, ASD and SCZ matched with clear similarity in transcriptomic features detected in the post-mortem brain (Gandal et al., 2018). These associations were replicated in our Chinese cohorts (Guo et al., 2018, 2019; Wang et al., 2016). Therefore, integrating data from multiple disorders with phenotypic similarity increased the statistical power of candidate gene discovery (Coe et al., 2019; Gonzalez-Mantilla et al., 2016; Li et al., 2016).

The functional analysis of candidate genes from both expression and functional networks provide clues to elucidate the molecular pathway related to these disorders, such as the brain-size-related genes (Li et al., 2017a), Vitamin D-related genes (Li et al., 2017b) and recessive genes (Wang et al., 2020) in ASD, as well as the genetic components related to three ASD subcategories (Li, Hu, et al., 2018), we previously reported. In addition, functional genomics of NPDs will reveal the characteristics of pleiotropic genes from disorder-specific genes, which may advance the diagnostic classification and treatment (Cross-Disorder Group of the Psychiatric Genomics Consortium. Electronic address and Cross-Disorder Group of the Psychiatric Genomics, 2019). By searching the scientific literature, we collected DNMs from 13,853 NPD cases and 3391 controls to perform a cross-disorder analysis of five types of NPDs: ASD, UDD, EE, ID and SCZ. We want to decipher perspectives of NPDs as follow: (1) the burden and contribution of DNMs in NPDs; (2) the prioritization of candidate genes; (3) the expression patterns and functional pathways of candidate genes.

Materials and Methods

Data Collection and Annotation

We collected DNMs detected by WGS or WES from 37 published studies and performed cross-disorder analysis (Table S1). We searched original articles in PubMed from 2010 to 2019 based on the terms of “de novo mutation”, “whole-exome sequencing” and “whole-genome sequencing”. The DNMs in ASD, UDD, EE, ID and SCZ were used for further analysis, because only these five NPDs have enough DNMs. Additionally, DNMs detected in unaffected individuals were also collected as negative control. ANNOVAR (Wang, Li, & Hakonarson, 2010) and our previously reported VarCards (Li, Shi, et al., 2018) were utilized to annotate DNMs based on a human reference genome (hg19). Based on the functional effects of variants, we classified DNMs into two classes as follow: (1) Coding region variant, including loss-of-function variant (LoF, including spliceing ≤ 2 bp), stopgain, and stoploss SNVs, and frameshift
indels), deleterious missense variant (Dmis), tolerant missense variant (Tmis), synonymous variant, (2) Noncoding region variant. The pathogenesis of missense variant was predicted by ReVe, recently developed by our group (Li, Zhao, et al., 2018). LoF and Dmis variant were combined as putative functional (Pfun) variants. We only focused on coding region variant in further analysis. All variants were available in our currently developed Gene4Denove database (Zhao et al., 2019).

**Burdens and Contributions Analysis of Different Types of DNMs**

To test which classes of DNMs contribute to each disorder, two-tailed Fisher’s exact test was used to compare the burden of DNMs of each NPD with unaffected control. As DNM data was collected from different publications, we normalized DNMs by the number of de novo synonymous variants based on the hypothesis that synonymous variants would be unrelated to phenotype and could potentially remove batch effects of DNM detection rate. To perform burden analysis, we constructed four number as follow: the count of specific class of DNMs (Dmis, LoF, Pfun) in case and control, and the count of de novo synonymous in case and control. Additionally, we used “ascertainment differentials” as described in previous work (Iossifov et al., 2014) to estimate the contribution of each class of DNMs to different NPDs and synonymous variants also were used to remove bias between different studies.

**Gene Set Overlap Across Five Disorders Based on De Novo Mutations**

We also used DNENRICH (Fromer et al., 2014; Shohat, Ben-David, & Shifman, 2017) to test whether genes that were detected to carry specific classes of DNMs (i.e., LoF, Dmis, and Pfun) in any two NPDs show of significant overlap. DNENRICH was a software that perform gene set enrichment based on gene size, structure, and local trinucleotide mutation rate. We performed 100,000 permutations which weight mutation number of each gene and compared observed and expected overlap of two gene set. The input of DNENRICH includes (1) gene carrying specific class of DNMs in one disorder, (2) genes carrying consistent class of DNMs in another disorder. The Benjamini and Hochberg false discovery rate procedure was used to adjust for multiple testing.

**Candidate Genes Prioritization Based on TADA**

The transmitted and de novo association (TADA) tool was used to perform statistical analysis based on recurrent of variants in same gene (He et al., 2013). Here, we used TADA-Denovo which only take DNMs into consideration. To prioritized candidate genes, we used two strategies in our analysis. Firstly, we performed TADA analysis of DNMs in each disorder. Secondly, we performed TADA analysis of the DNMs in five NPDs based on the hypothesis that NPDs shared genetically components. Genes with FDR (q-value) < 0.05 in either of above two strategies were prioritized as candidate genes. Genes with Pfun DNMs in at least two disorders were classified as shared genes, and genes with DNMs in only one disorder were classified as unique genes.

**Expression Patterns and Functional Networks Analysis**

As in our previous study (Li et al., 2017a), we performed weighted gene coexpression network package (WGCNA; Langfelder & Horvath, 2008) to RNA-seq data of 524 brain samples from the BrainSpan database with the power of six to depict the spatiotemporal expression patterns of candidate gene. In addition, we sourced transcriptome data of 526 prenatal neocortical samples from the BrainSpan database with the power of three to characterize neocortical expression profiles of candidate gene. The other consensus parameters of WGCNA for spatiotemporal expression pattern and prenatal neocortical samples are as follow: minModuleSize = 20, mergeCutHeight = 0.25, corType = “pearson”. In addition, to construct functional networks of candidate genes, we calculated the Pearson correlation coefficients between any two genes based on the RNA-seq data of 524 brain samples from the BrainSpan database mentioned above, and gene pairs with lRl> 0.8 were regarded as expressed. Protein–protein interaction (PPI) data with a combined score higher than 400 according to the version 10.5 of STRING (Szklarczyk et al., 2019) database were also incorporated to construct a functional network. Cytoscape v3.6.1 (https://cytoscape.org/) was used to visualize the functional network.

**Gene Functional Enrichment**

To investigate the function of candidate gene, we used Metascape tool (http://metascape.org/) with default parameters to perform functional enrichment analysis in three gene ontology (GO) including molecular function, cellular component and biological process for all candidate genes (Zhou et al., 2019). In addition, we performed functional enrichment of candidate genes in each independent coexpression module identified by WGCNA to identify specific function.
Results

Pfun DNMs Involved in the Five NPDs with Burden and Contribution

In total, we collected 23,110 DNMs in coding regions from 17,244 trio-based WES/WGS studies, including 8175 DNMs from 6511 patients with ASD, 7696 DNMs from 4293 patients with UDD, 1165 DNMs from 933 patients with EE, 1393 DNMs from 1022 patients with ID, 1052 DNMs from 1094 patients with SCZ, and 3629 DNMs from 3391 unaffected controls (Table S1). The DNMs were available in Gene4Denove database, recently developed by our group (Zhao et al., 2019). After controlling for batch effects with synonymous variants, we found that all the five NPDs carried significantly more LoF and Dmis DNMs, as well as the combination of two classes of DNMs (i.e., Pfun) but not Tmis DNMs, suggesting that Pfun DNMs are involved in all the five disorders (Table 1; Fig. S1). However, different degree of mutation burden for the five NPDs. First, we found that Pfun DNMs exhibited a high degree of mutation burden in patients with EE (odds ratio, OR = 2.45), ID (OR = 2.36), and UDD (OR = 1.77). Second, Pfun DNMs in ASD (OR = 1.33) were moderately higher than those in the control. Thirdly, SCZ (OR = 1.28) presented with the lowest difference of Pfun compared to the control.

We then evaluated the contribution of Pfun DNMs to NPDs based on “ascertainment differentials” of DNMs, a method based on the bias of DNMs events per child between patients and controls, as previous study (Iossifov et al., 2014). As a result, we found that 43.61% LoF and 33.93% Dmis DNMs contribute to 10.22% and 10.94% of overall NPD patients, respectively (Table 1). Specifically, 64.61%, 55.90%, 48.72%, 33.06% and 21.85% of LoF DNMs contribute in 19.53% of ID, 11.50% of EE, 15.68% of UDD, 6.24% of ASD, and 2.72% of SCZ patients, respectively. In addition, we noted that 61.03%, 51.87%, 39.86%, 18.92%, 21.11% of Dmis DNMs contribute in 22.90%, 18.58%, 17.62%, 4.75%, and 4.19% of EE, ID, UDD, ASD and SCZ patients, respectively. Together, Pfun DNMs presented a gradient of effect sizes and contributed in 38.11%, 34.40%, 33.31%, 10.98% and 6.91% of patients with ID, EE, UDD, ASD and SCZ, respectively. These results suggested that DNMs play strong roles in the etiology of ID, EE, and UDD, and moderate roles in ASD, compared to general roles in SCZ.

Genetic Similarity Among the Five Disorders

Due to the clinical similarity between NPDs, we explored genes overlap among the five disorders based on DNMs with different functional effects. We found that genes with LoF, Dmis, as well as Pfun DNMs were significantly shared among the five disorders. However, a compellingly divergent degree of genes overlap was also observed (Fig. 1; Table S2). Specifically, we found a high degree of overlapping Pfun genes between UDD and ID [padj = 3.85E−5, with an observed-to-expected ratio (O/E) = 10.51], EE and ID [padj = 3.85E−5, (O/E) = 8.21], and UDD and EE [padj = 1.11E−4, (O/E) = 6.03]. We also observed that ASD showed a secondary (lesser) degree of genetic overlap with ID [padj = 3.85E−5, (O/E) = 4.33], EE [padj = 9.73E−5, (O/E) = 3.36] and UDD [padj = 3.85E−5, (O/E) = 3.35]. Although SCZ and EE showed significant overlap with ASD, ID and UDD, but SCZ and EE [(O/E) = 1.59, padj = 0.097] were only very slightly genetically overlap with each other.

Cross Disorder Analysis Prioritize Novel Candidate Gene

Based on the TADA model for Pfun DNMs in five disorder, we prioritized 279 candidate genes (FDR < 0.05), containing 59, 202, 43, and 66 genes in ASD, UDD, EE, and ID, respectively (Table S3). Due to the smaller number of sample size and less contribution of DNMs, we did not prioritize any candidate genes in SCZ by single-disorder analysis. Since these five disorders presented significant genetic similarity, we also integrated Pfun DNMs in these five disorders. As a result, we prioritized 238 candidate genes with FDR < 0.05, including 42 novel candidate genes that were not included in the above 279 candidate genes (Table S3). In addition, we also noted that 43 of the 238 candidate genes showed stronger statistical evidence by integrated analysis. After removing redundancy between the above two strategies, 321 candidate genes were finally prioritized (Table 2). We found that Pfun DNMs of these candidate genes account for 27.37%, 26.81%, 21.54%, 7.14%, and 3.20% patients with SCZ, UDD, ID, EE, and ASD, respectively (FDR ≤ 0.0001, n = 34), tier 2 (0.0001 < FDR ≤ 0.001, n = 34), tier 3 (0.001 < FDR ≤ 0.01, n = 54), and tier 4 (0.01 < FDR < 0.05, n = 107). In addition, 26.48% (85/321) of candidate genes carrying Pfun DNMs in only one disorder and 32.71% (105/321), 27.10% (87/321), 13.71% (44/321) of candidate genes carrying Pfun DNMs in two, three, and at least four disorders, respectively (Table 2). For example, ATP1A3 (FDR = 2.61E−5), PBX1 (FDR = 3.95E−6) carried Pfun DNMs in three disorders and KIAA2022 (FDR = 6.34E−7),
Table 1  Burdens and contributions of different classes of DNMs in five disorders

| Disorders (N) | Category | LoF | Dmis | Pfun | Tmis | Synonymous |
|---------------|----------|-----|------|------|------|------------|
| ASD (6511)    | DNMs     | 1228| 1633 | 2861 | 3406 | 1864       |
| p             | 6.80E−09 | 6.00E−04 | 9.81E−08 | 0.20 |
| p<sub>adj</sub> | 2.72E−08 | 8.00E−04 | 1.96E−07 | 0.20 |
| OR            | 1.49     | 1.23 | 1.33 | 1.07 |
| 95% CI        | 1.30−1.72 | 1.09−1.39 | 1.20−1.48 | 0.97−1.18 |
| Clinical implicated DNMs (%) | 33.06 | 18.92 | 24.99 |
| Contribute to patients (%) | 6.24 | 4.75 | 10.98 |
| UDD (4293)    | DNMs     | 1,382| 1,898| 3,280| 2,676| 1,607      |
| p             | 2.11E−22 | 6.66E−17 | 6.15E−26 | 0.60 |
| p<sub>adj</sub> | 4.22E−22 | 8.88E−17 | 2.46E−25 | 0.60 |
| OR            | 1.95     | 1.66 | 1.77 | 0.97 |
| 95% CI        | 1.70−2.24 | 1.47−1.88 | 1.59−1.97 | 0.88−1.08 |
| Clinical implicated DNMs (%) | 48.72 | 39.86 | 43.59 |
| Contribute to patients (%) | 15.68 | 17.62 | 33.31 |
| EE (933)      | DNMs     | 192 | 350  | 542  | 414  | 192        |
| p             | 5.03E−12 | 1.66E−20 | 1.90E−22 | 0.018 |
| p<sub>adj</sub> | 6.71E−12 | 3.32E−20 | 7.60E−22 | 0.018 |
| OR            | 2.27     | 2.57 | 2.45 | 1.26 |
| 95% CI        | 1.79−2.88 | 2.09−3.16 | 2.03−2.97 | 1.04−1.53 |
| Clinical implicated DNMs (%) | 55.90 | 61.03 | 59.22 |
| Contribute to patients (%) | 15.68 | 17.62 | 33.31 |
| ID (1022)     | DNMs     | 309 | 366  | 675  | 447  | 248        |
| p             | 7.94E−24 | 2.91E−14 | 2.23E−24 | 0.59 |
| p<sub>adj</sub> | 1.59E−23 | 3.88E−14 | 8.92E−24 | 0.59 |
| OR            | 2.82     | 2.08 | 2.36 | 1.05 |
| 95% CI        | 2.2−3.48 | 1.71−2.52 | 1.99−2.81 | 0.88−1.26 |
| Clinical implicated DNMs (%) | 64.61 | 51.87 | 57.70 |
| Contribute to patients (%) | 19.53 | 18.58 | 38.11 |
| SCZ (1094)    | DNMs     | 136 | 217  | 353  | 450  | 241        |
| p             | 0.045    | 0.028 | 0.011 | 0.35 |
| p<sub>adj</sub> | 0.060    | 0.056 | 0.044 | 0.35 |
| OR            | 1.28     | 1.27 | 1.27 | 1.09 |
| 95% CI        | 1.00−1.64 | 1.02−1.57 | 1.05−1.54 | 0.91−1.31 |
| Clinical implicated DNMs (%) | 21.85 | 21.11 | 22.40 |
| Contribute to patients (%) | 19.53 | 18.58 | 38.11 |
| NPDs (13,853) | DNMs     | 3247| 4464 | 7711 | 7393 | 4152       |
| p             | 3.53E−20 | 4.68E−14 | 1.85E−22 | 0.39 |
| p<sub>adj</sub> | 7.06E−20 | 6.24E−14 | 7.40E−22 | 0.39 |
| OR            | 1.77     | 1.51 | 1.61 | 1.04 |
| 95% CI        | 1.56−2.01 | 1.36−1.69 | 1.46−1.78 | 0.95−1.14 |
| Clinical implicated DNMs (%) | 43.61 | 33.93 | 38.01 |
| Contribute to patients (%) | 10.22 | 10.94 | 21.16 |
| Control (3391)| DNMs     | 411 | 662  | 1073 | 1595 | 932        |

“Clinical implicated DNMs” means the estimated proportion of DNMs in each disorder involved in the etiology of disorders. “Contribute to patients” means the proportion of patients can be interpreted by DNMs based on the clinical implicated DNMs. We performed a Fisher exact test, which normalizes by the number of de novo synonymous mutations in each condition to adjust the batch effects in different studies. The Benjamini and Hochberg false discovery rate (FDR) procedure was used to adjust for multiple testing. p<sub>adj</sub> below 0.05 were highlighted in bold

ASD autism spectrum disorder, UDD undiagnosed developmental disorder, EE epileptic encephalopathy, ID intellectual disability, SCZ schizophrenia, NPDs neuropsychiatric disorders, integration of these five disorders, DNMs de novo mutations, OR odds ratio, CI confidence interval, Dmis deleterious missense variants as predicted by ReVe, Tmis tolerant missense variants, LoF loss-of-function variants including frameshift, stoploss and stopgain, splicing variants, Pfun putative functional variant including Dmis and LoF variants
AGO1 (FDR = 3.31E−6), NACC1 (FDR = 4.38E−4) in four 
disorders, and increase significant genetic evidence from com-
bined analysis. To test the disorder bias (one disorder harbor 
significant enrichment of DNMs in specific gene than other 
disorders) of specific candidate gene, we performed Poisson 
rate test as our previous studies (Li et al., 2016). For the 236 
candidate genes carrying Pfun DNMs in at least two disor-
ders, we found that 51 genes also presented disorder bias, 
including 33 genes in UDD, 11 genes in EE, seven genes in 
ID (Table S5).

In three recent studies (Coe et al., 2019; Gonzalez-Mantilla 
et al., 2016; Nguyen et al., 2017) which integrated rare vari-
ants and/or DNMs in multiple NPDs to identify risk genes, 
64.49% (207/321) of candidate genes were identified, com-
pared to 35.51% (114/321) genes being identified here (Fig. 
S2). Among these 114 novel candidate genes, 5, 9, 32, 68 
genes were classified into tier 1 (KIAA2022, KCNT1, ATP1A3, 
NALCN, SOX11), tier 2 (GFOD2, SLC22A23, SNAP25, 
NACC1, RFX3, AKT3, LOC400927-CSNK1E, DHDDS), tier 
3, and tier 4, respectively. We performed literature searches to 
find genetic or functional evidence of these novel candidate 
genes, and found 54.39% (62/114) of which were reported 
associated with human brain disorders. Moreover, 85.71% 
(12/14) of novel candidate genes in tier 1 and tier 2 associated 
with neurodevelopmental disorders (Table S6).

Expression Patterns and Characteristics 
of Candidate Gene

The spatiotemporal expression patterns of candidate genes 
represent a quantitative phenotype that provides an in-depth 
view of the molecular pathways disrupted in NPDs. Based 
on transcriptomic data of brain samples from the BrainSpan 
database, we found that 250 of 321 genes could be classified 
to two independent modules (M1–M2) with highly similar 
expression patterns during development (Fig. 2a; Table S7). 
Genes in M1 (68.4%, 171/250) exhibited high expression 
in embryonic and early-to-middle fetal periods [8–24 post-
conceptual weeks (pcw)] and then gradually decreased. In 
contrast, candidate genes in M2 (31.6%, 79/250) showed low 
expression during prenatal periods. We then tested whether 
candidate genes with FDR < 0.05 in each disorder were sig-
nificantly enriched in specific modules compared to all can-
didate genes in the coexpression modules and found that 26 
of 43 (60.47%) EE genes belonged to M2 (Fisher’s exact test, 
p = 7.07E−6, OR = 4.66, 95% CI 2.30–7.67) and only 8 of 43 
(18.60%) EE genes in M1 (Fisher’s exact test, p = 1.55E−5, 
OR = 4.97, 95% CI 2.18–12.79) (Fig. 2b). In addition, genes 
with Pfun DNMs existing in several disorders were more 
likely to belong to coexpression modules (Ordered logistic 
regression, p = 2.07E−7) including chromatin related M1 
(Ordered logistic regression, p = 1.08E−2) and synapse 
related M2 (Ordered logistic regression, p = 3.81E−2), sug-
gesting the profound effect of chromatin and synapse on the 
etiology of multiple disorders.

Since the expression levels of candidate genes changed 
dramatically in the human brain during the fetal period 
(described above), we characterized the profiles of candidate 
genes based on prenatal neocortical samples from the Brain-
Span database. Here, we identified three modules (Ma–Mc) 
involved in 210 of 321 candidate genes with distinct laminar 
neocortical expression patterns (Fig. 2c; Table S7). Genes
Table 2  Prioritized candidate genes with FDR <0.05 in this study

| Rank | Unique genes (26.48%, n = 85) | Shared genes in two disorders (32.71%, n = 105) | Shared genes in three disorders (27.10%, n = 87) | Shared genes in at least four disorders (13.71%, n = 44) |
|------|-------------------------------|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------|
| FDR ≤ 0.0001 (39.25%, n = 126) | HDAC8, KANSL1, ZBTB18, CNKSR2, BTF3, MSL3, PDHA1 | SATB2, GATAD2B, KAT6B, MEF2C, SMC1A, CDK5, SMARCA2, KDM5B, NDF1, EHMT1, HNRNPU, PTPN11, CTCF, CNOT3, TBR1, NFI, PPP1CB, KIF1A, GNAI1, CHAMPI, KCNHI, NAA5, UFP1B, PIK3CA, MAPK4, UNC80, KCNT1, KDM6A, ZC4H2, SMAD4, WDR26, SOX11 | SLC6A1, FOXP1, CTNNB1, TCF4, SETD5, PPP2R5D, ASXL3, MED13L, SCN1A, DYRK1A, ADNP, EP300, PURA, WDR45, CDK13, TBL1XR1, IRF2BP1, PIBN, KAT6A, DNM1, PASC1, SHANK3, TRIP12, PPM1D, NAA10, TCF20, CLIC, SET*, BRAF, CACNA1A, BCL11A, CHD3, EFTUD2, SMARCA4*, SOX5, HECW2, KMT5B**, FBXO11**, USP9X, DLG4, PBX1**, MYT1L**, TCF7L2**, NR2F1**, ATP1A3**, SLC35A2**, NALCN, NSD2**, ANK2 | CHD8, CHD2, POGZ, STXBPI, KCNQ2, KMT2A, ANKRD11, DDX3X, ARID1B, SCN8A, GRIN2B, CSNK2A1, WAC, FOXG1, CASK, IQSEC2, AHDC1, EEF1A2, TLK2*, DNMT3A*, GABRB2, CREBBP, COL4A3BP, PUF60, CACNA1E*, GABRB3**, KIAA2022**, CUL3**, SMC3*, PHIP, CHD4, IPTR1, KCNQ3*, AGO1**, MEC2P2, SYNGAP1, SC2A, GNAO1 |
| 0.0001 < FDR ≤ 0.001 (10.59%, n = 34) | GFOD2, MYO1E, TAO1, PRKAR1A, AKT3, SLC12A2, HNRNPK, AGO2 | QRIC1, EBF3, PPP2R1A, CAMK2A*, RAB11A, RAC1, SNAP25*, USP7, TNPO2, SYT1, SIN3A | FOXP2*, HIST1H1E*, GABBR2, MBDS**, SETBP1, ZMYND11*, SLC22A23*, KCNBI, CSNKE*, SYNCRIP*, RFX3**, LOC400927-CSNKE*, DHDDS* | GRIN2A, NACCI |
| 0.001 < FDR ≤ 0.01 (16.82%, n = 54) | TAB2, MORC2, WDFY3, TCF12, PRKGI, SDX3, BRD7, SOX4, ASB4, KCNA2, C9orf142, PHF5A, Clorf123, LMO2, VAMP2, PLAC8L1, HIST1H4C, SNX11 | CYP27C1, ARHGEF9, HK1, POU3F3, FGF12, CBL, PPP2CA, CSNK2B, SFI, TNPO3, ASXL1, PRKD1*, ER2, HIST1H4E, CAMK2B, AUTS2, PHF7, NTRK2, FANCE, RNF146, LAMBI*, FAM200A, SSBP3, PRPF8, FIGN, YWHAG*, GABRA1, SRCAP*, TUBA1A, BRPF1, GABRG2, CPSF7, SPAST, NRXN1*, DSCAM | DYNC1H1 |
Candidate genes are split into four parts based on the number of disorders with putative functional DNMs in specific gene. Unique genes with superscripts letters including a, u, e, i, s represents genes only carry putative functional DNMs in ASD, UDD, EE, ID, SCZ respectively. We ranked all candidate genes into four tiers based on the strength of FDR. The number of asterisks on the genes indicate the increased ranks of candidate genes by cross disorders analysis compared to individual disorder analysis.

| Rank | Unique genes (26.48%, \( n = 85 \)) | Shared genes in two disorders (32.71%, \( n = 105 \)) | Shared genes in three disorders (27.10%, \( n = 87 \)) | Shared genes in at least four disorders (13.71%, \( n = 44 \)) |
|------|---------------------------------|------------------------------------------------|------------------------------------------------|------------------------------------------------|
| 0.01 < FDR ≤ 0.05 (33.33%, \( n = 107 \)) | EBF2\(^a\), PDX1\(^a\), PLEKHB2\(^a\), HIST1H2AC\(^a\), TAF13\(^a\), FAM104A\(^a\), SMPD4\(^u\), MPPED2\(^u\), GOLPH3\(^a\), RAD51\(^u\), FOSL2\(^a\), GALNT18\(^u\), PI4KB\(^u\), PRSS4\(^u\), PRKAR1B\(^u\), SIAH1\(^u\), LARP7\(^a\), EIF4A2\(^u\), COL23A1\(^u\), ATP8A1\(^i\), RAB11B\(^a\), GIGYF1\(^a\), MS1\(^i\), SMPD2\(^a\), PISD\(^a\), ZBTB10\(^a\), DCAF7\(^a\), NONO\(^a\), RPUS4\(^i\), GRIA2\(^a\), TMEM26\(^a\), FXYD5\(^a\), IL1RAPL2\(^a\), TGFB2\(^a\), NFE2L2\(^a\), ACHE\(^a\), FAM84A\(^a\), PAPOLG\(^a\), PNKD\(^a\), ERBB4\(^a\), CLDN5\(^a\), ATP1B1\(^a\), SGCE\(^a\), NUDT17\(^a\), SNRPB2\(^a\), ACTC1\(^a\), GABRP\(^a\), GNB1\(^a\), ILF2\(^a\), LRR3C\(^a\), NR6A1\(^a\), STK3\(^a\) | ANO3, G3BP1, CLCN4, DCX, MAP2K1, VEZF1, ASH1L, SMARCD1, KCNQ5, ENO1, STXB3P1, LZTR1, AGO3, RPL26, GRK1, CELF2, EYA1, PDK2, TFAP2C, COL4A1, LMTK3, PRR14L, TCTE3, NUDT4, GIKA2, ARHI1, GNAS, MEIS2, BIRC5, DOCK1, TIFA, DPF2, H2AFV, AB2, MECOM, CFAP45, TFAP4 | ARHGAP15, SMAD6, DAF1, NR4A2, TANC2, GNB2, SMARCC2, TAF1, KIFSC, RPL4, PSD3, MARK2, PHF21A, UGT1A3, SPRED2 | SON, GRIN1, RBM12 |
in Ma (57.62%, 121/210) were high expressed in the middle to upper layers. However, genes in Mb (23.81%, 50/210) presented a relatively reversed expression pattern compared to Ma. Genes in Mc (18.57%, 39/210) showed a relatively stable expression level in different layers. Similar to spatio-temporal expression patterns described above, convergent and divergent features were observed in different disorders (Fig. 2d). Specifically, 58.14% (25/43) of EE genes belonged to Ma (Fisher's exact test, p=0.013, OR =2.29, 95% CI 1.15–4.66). In addition, genes carrying Pfun DNMs in a higher number of disorders were more likely to be enriched coexpression modules (Ordered logistic regression, p = 1.60E−3), particularly in Ma (Ordered logistic regression, p = 6.59E−6), along with a concurrent enrichment in synaptic related function.

Functional Network and Characteristics of Candidate Gene

We next constructed a network which contained 84.11% (270/321) of the candidate genes that were co-expressed at mRNA level and/or displayed interactions at the protein level.
level (Fig. 3a). We noted that 208 of 270 genes (77.04%) in the functional network were shared genes, compared to 28 of 51 genes (54.90%) that were not included in the network (Fisher’s exact test $p = 7.18 \times 10^{-3}$, OR = 2.51, 95% CI 1.26–4.94). In addition, genes in the network carrying Pfun DNMs in a higher number of disorders showed more interconnectedness with others based on both coexpression data (Spearman’s rank correlation $R = 0.21$, $p = 1.58 \times 10^{-5}$, Fig. 3b) and protein–protein interaction data (Spearman’s rank correlation $R = 0.20$, $p = 3.71 \times 10^{-4}$, Fig. 3b) suggesting that shared
genes were more likely to be hub gene. Moreover, we found that genes shared by more disorders were more likely to be intolerant to mutation based on two different methods, residual variation intolerance score (RVIS; Petrovski et al., 2013) (Spearman’s rank correlation = −0.44, p = 1.71E−15, Fig. 3b) and Aggarwala constraint metrics (Aggarwala & Voight, 2016) (Spearman’s rank correlation = 0.43, p = 3.60E−12, Fig. 3b). These results suggested that genetic variants of shared genes may presented higher penetrance by regulating more genes.

Subsequently, we performed functional annotation and identified several gene ontology (GO) terms involved in NPDs based on the 321 candidate genes, including chromatin, chromosome, synapse and neuron related function (Fig. 3c). We found that EE genes were more likely to be involved in synapse relation function (20/43, Fisher’s exact test, p = 1.28E−3, OR = 3.08, 95% CI 1.48–6.37), but not chromatin (3/43, Fisher’s exact test, p = 1.43E−3, OR = 5.50, 95% CI 1.69–28.47) (Fig. 3d). In addition, candidate genes with Pfun DNMs in multiple disorders were more likely to have enriched chromatin function (Ordered logistic regression, p = 0.023) as well as synaptic function (Ordered logistic regression, p = 0.014), suggesting essential roles for these two pathways in the common etiology in NPDs.

Discussion

The high heritability of NPDs provides an opportunity to understand their etiologies from a genetic perspective. DNMs with strong functional effects have been widely demonstrated to significantly contribute to the etiology of NPDs. Therefore, we try to integrate DNMs data from five NPDs with phenotypic similarity to identify novel candidate gene and decipher the association among NPDs from new perspectives.

Our data showed that Pfun DNMs rather than Tmis and synonymous DNMs play broad roles in the five NPDs, along with compellingly different degrees of DNM burden and contribution to phenotypes. First, ID, EE and UDD presented a high degree of DNMs burden and we estimated that Pfun DNMs contributed to these NPDs in more than 30% of patients. Our results strengthen previous studies which showed that DNMs result in a diagnostic yield of 42%, 40% and 26.9% for UDD (Deciphering Developmental Disorders, 2017), ID (Gilissen et al., 2014), and EE (Hamdan et al., 2017), respectively. Second, ASD presented a moderate degree of DNMs burden, and Pfun DNMs contributing in about 10% of patients with ASD. Other genetic variants might be involved in the etiology of ASD, such as de novo promoter variants (An et al., 2018) and common variants (Grove et al., 2019). Additionally, patients with ASD also present phenotype of developmental delay and ID (Iossifov et al., 2014; Martin et al., 2018). Currently study found that patients carrying DNMs in ASD-NDD genes (gene carrying more DNMs in other neurodevelopment disorder than ASD) exhibited later walk and lower IQ than patients carrying DNMs in ASD-predominant genes (gene carrying more DNMs in ASD than other neurodevelopmental disorder) (Satterstrom et al., 2020). However, DNMs also significant contribute to ASD when removed the influence of IQ (Satterstrom et al., 2020). Third, SCZ showed the lowest degree of DNMs burden and contribution, indicating that DNMs are probably not the major genetic factor for the etiology of SCZ. Our results expand on the highly polygenic nature of previous studies which reported that common variants could account for over 30% of SCZ (Li et al., 2017c; Ripke et al., 2013), along with more than one hundred of SCZ-associated loci having been identified by GWAS (Li et al., 2017c).

We then estimated genetic association and observed significant overlaps in genes with LoF, Dmis, and Pfun DNMs among the five disorders. We found that UDD, ID and EE showed the strongest genetic similarity [(O/E) > 6], providing genetic evidence for the strong comorbidity observed among these three disorders. For example, a previous clinical investigation showed that 41.6% of patients with severe ID had symptoms of epilepsy (Robertson et al., 2015). In addition, ASD also showed relatively moderate genetic overlap with UDD, EE and ID [3 < (O/E) < 4]. Furthermore, SCZ was slightly but significantly correlated with ID, UDD and ASD [1 < (O/E) < 3]. Although we did not observe significant overlap of genes between SCZ and EE [(O/E) = 1.59, padj = 0.097], the trends suggest that they are genetically associated. We encourage further studies could investigate the associations between SCZ and EE based on larger sample size.

We totally prioritized 321 candidate genes including 35.51% (114/321) candidate genes that were not reported in previous cross-disorder studies (Coe et al., 2019; Gonzalez-Mantilla et al., 2016; Nguyen et al., 2017), which might be attributed to the integration of a larger sample size of disorders than previously and increased the statistical power. Based on literature search 54.39% (62/114) these novel candidate genes were reported associated with human brain disorders and 85.71% (12/14) of high confidence genes in tier 1 and tier 2 associated with neurodevelopmental disorders. These results highlight the advantages of integration of genetic data from different disorders with similar phenotypes. We noted that 73.52% (236/321) of candidate gene carry Pfun DNMs in at least two disorders, suggesting that DNMs with different functional effects in certain genes contributed to the differential etiology of the disorders. For example, missense mutations in SCN2A (Ben-Shalom et al., 2017; Wolff et al., 2017) presented as gain-of-function in early onset EE and loss-of-function in late onset EE and ASD, respectively. The mutations in GABRB3 (Shi et al.,
and GRIN2D (XiangWei et al., 2019) also exhibited complexity of the pathological mechanisms. In addition, patients with DNMs in shared genes may exhibit wide range of phenotypes, but original studies only give priority to a certain disorder. For example, a large sequencing study used ASD as the inclusion criteria but took other comorbidities (ID/EE) into secondary consideration (Iossifov et al., 2014). It is important to recheck clinical phenotype, once a patient that was diagnosed with one NPD carrying Pfun variant in candidate gene of another NPD. It should also be noted that 21.61% (51/236) of shared genes carrying Pfun DNMs were biased to a specific disorder including 33 genes in UDD, 11 genes in EE and seven genes in ID, which consistent with recent findings (Coe et al., 2019). A recent study employed large-scale exome sequencing in ASD and identified 102 ASD-related risk genes (Satterstrom et al., 2020). The disorder bias of gene in our findings are also in agreement with this study. For example, 79.31% (23/29) of the Pfun DNMs were detected in patients with EE and was defined as one of the “seed” gene to discover the gene group that related with EE in current study (Chow et al., 2019). We observed that 26.48% (85/321) candidate genes carrying Pfun DNMs were present in only one disorder. Unique genes and biased genes suggest that a definition of “molecular endophenotypes” should be used in genetic counselling and genetic diagnosis, as “functional cellular endophenotypes” (Lago et al., 2018). Molecular endophenotypes represent a plausible strategy to summarize complex NPDs with high clinical heterogeneity, by separating them into different subtypes with similar pathogenic mechanisms based on DNMs, such as MECP2 variants in patients with Rett syndrome (Amir et al., 1999; Tillotson et al., 2017).

The expression patterns and functional networks of candidate genes represent quantitative phenotypes and provide an in-depth view of NPDs (Li, Santpere, et al., 2018; Parikshak et al., 2013). Our results showed that candidate genes associated with NPDs presented specific spatiotemporal expression patterns in the human brain and prenatal neocortex, reflecting the wax and wane function of candidate genes at different times and in regions of the brain. We identified two spatiotemporal expression patterns of candidate genes (Fig. 2a). Genes in M1 exhibited high expression in embryonic and early-to-middle fetal periods and related to chromatin modification which associated with expression regulation. In contrast, candidate genes in M2 showed high expression during postnatal periods and related to synaptic communication (Fig. 2b). These expression pattern consistent with current study which found that genes involved in expression regulation high express during prenatal time and in neuronal communication genes high express during postnatal time (Satterstrom et al., 2020). Disruptive DNMs in synaptic communication related gene might impact on neurotransmission in ASD and other neurodevelopmental disorders, whereas chromatin modification related gene might regulate functional pathway that associate with these disorders. An example is that patients carrying disruptive mutations in chromodomain related gene CHD8 and its target genes exhibited similarly clinical phenotypes (Beighley et al., 2020). Candidate genes for EE exhibited more specific features related to their expression pattern and functional pathways comparing to ASD, ID and UDD. More importantly, genes with Pfun DNMs shared by more disorders were more intolerant to genetic variants and were more likely to participate in chromatin and synaptic function, highlighting the core roles of shared genes and these two functional pathways in maintaining the normal function of human brain. Dysfunction of shared genes may cause the cascading paralysis of biological processes and contribute significantly to the occurrence of multiple disorders.

We acknowledge several limitations in this study. First, integrated DNMs derived from several different cohorts would increase the statistical power of candidate gene detection, but due attention should be paid to the lack of uniform quality control among different studies. Although we used synonymous DNMs as standardizations to remove confounding factors, bias maybe still be present. Second, an unbalanced sample size among NPDs might also influence the power of discoveries for each disorder. Third, we prioritized several candidate genes with strong statistical support but lack functional experiments. Fourth, both genetic and environmental factors are involved in the etiology of NPDs, and the combination of these factors should be the topic of further research to fully understand the etiology of NPDs.

This study demonstrated that DNMs play relatively strong roles in NPDs. In addition, significant genes overlap among the five NPDs has provided genetic evidence for clinical comorbidity, which consistent with previous proposed to encompass genetic data of a wide spectrum of neuropsychiatric disorders to identify candidate gene (Moreno-De-Luca et al., 2013). Genotype–phenotype correlation analysis of candidate genes prioritized in this study are required in the future to strengthen genetic evidence and further for genetic counseling and the clinical assessment of NPDs. The expression patterns and functional network offer novel insight for the shared and unique genetic mechanisms in the etiology of NPDs.

Supplementary Information The online version contains supplementary material available at https://doi.org/10.1007/s10803-021-05031-7.

Acknowledgments This work was supported by the National Natural Science Foundation of China (81730036 and 81525007 to KX; 31601027 to ZSS; 81801133 to JCL), the Key R&D Program of Hunan Province (2016JC2055 to KX), Science and Technology Innovation Leader of Hunan Province (2016RS2001 to KX), Young Elite Scientist
Sponsorship Program by CAST (2018QNPC001 to JCL), Innovation-Driven Project of Central South University (20180033040004 to JCL), and the Natural Science Foundation of Hunan Province for outstanding Young Scholars (2020JJ3059).

Author Contributions JL, ZS, XX designed and supervised the study. KL, ZF, GZ, BL, LX, LW, TL, XW,ZW participated in literature search and data collection. JL, KL, YZ, YJ performed data analysis, and figure and table preparation. JL, KL wrote the manuscript with input from all authors. CC, QP, ZH, HG, BT, CL, ZS, XX participated in review of manuscript and offer valuable advices. All authors read and approved the final manuscript.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

Adam, D. (2013). Mental health: On the spectrum. Nature, 496, 416–418. https://doi.org/10.1038/496416a
Aggarwala, V., & Voight, B. F. (2016). An expanded sequence context model broadly explains variability in polymorphism levels across the human genome. Nature Genetics, 48, 349–355. https://doi.org/10.1038/ng.3511
Amir, R. E., Van den Veyver, I. B., Wan, M., Tran, C. Q., Francke, U., & Zoghbi, H. Y. (1999). Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2. Nature Genetics, 23, 185–188. https://doi.org/10.1038/13830
An, J.-Y., Lin, K., Zhu, L., Welring, D. M., Dong, S., Brand, H., Wang, H. Z., Zhao, X., Schwartz, G. B., Collins, R. L., Currall, B. B., Dastmalchian, C., Dea, J., Duhin, C., Gilson, M. C., Klei, L., Liang, L., Markenoff-Popadimitriou, E., Pocheddy, S., Ahituv, N., et al. (2018). Genome-wide de novo risk score implicates promoter variation in autism spectrum disorder. Science. https://doi.org/10.1126/science.aat6576
Beighl, J. S., Hudac, C. M., Arnett, A. B., Peterson, J. L., Gerds, J., Wallace, A. S., Mefford, H. C., Hoekzema, K., Turner, T. N., O’Roak, B. J., Eichler, E. E., & Bernier, R. A. (2020). Clinical phenotypes of carriers of mutations in CHD8 or its conserved target genes. Biological Psychiatry, 87, 123–131. https://doi.org/10.1016/j.biopsych.2019.07.020
Ben-Shalom, R., Keeshen, C. M., Berrios, K. N., An, J. Y., Sanders, S. J., & Bender, K. J. (2017). Opposing effects on NaV1.2 function underlie differences between SCN2A variants observed in individuals with autism spectrum disorder or infantile seizures. Biological Psychiatry, 82, 224–232. https://doi.org/10.1016/j.biopsych.2017.01.009
Bernier, R., Golzio, C., Xiong, B., Stessman, H. A., Coo, B. P., Penn, O., Witherspoon, K., Gerds, J., Baker, C., Vulto-van Silfhout, A. T., Schuurs-Hoeijmakers, J. H., Fichera, M., Bosco, P., Buono, S., Alberti, A., Failla, P., Peeters, H., Steyaert, J., Vissers, L. E. L. M., Francescato, L., et al. (2014). Disruptive CHD8 mutations define a subtype of autism early in development. Cell, 158, 263–276. https://doi.org/10.1016/j.cell.2014.06.017
Chow, J., Jensen, M., Amini, H., Hormozdari, F., Penn, O., Shifman, S., Giri-rajan, S., & Hormozdari, F. (2019). Dissecting the genetic basis of comorbid epilepsy phenotypes in neurodevelopmental disorders. Genome Medicine, 11, 65. https://doi.org/10.1186/s13073-019-0678-y
Coe, B. P., Stessman, H. A. F., Sulovari, A., Geisheker, M. R., Bakken, T. E., Lake, A. M., Dougherty, J. D., Lein, E. S., Hormozdari, F., Bernier, R. A., & Eichler, E. E. (2019). Neurodevelopmental disease genes implicated by de novo mutation and copy number variation morbidity. Nature Genetics, 51, 106–116. https://doi.org/10.1038/s41588-018-0288-4
Craddock, N., & Owen, M. J. (2010). The Kraepelinian dichotomy—Going, going... but still not gone. British Journal of Psychiatry, 196, 92–95. https://doi.org/10.1192/bjp.bp.107.073429
Cross-Disorder Group of the Psychiatric Genomics Consortium. (2013). Identification of risk loci with shared effects on five major psychiatric disorders: A genome-wide analysis. Lancet, 381, 1371–1379. https://doi.org/10.1016/S0140-6736(12)62129-1
Cross-Disorder Group of the Psychiatric Genomics Consortium. (2019). Genomic relationships, novel loci, and pleiotropic mechanisms across eight psychiatric disorders. Cell, 179, 1469-1482. e11. https://doi.org/10.1016/j.cell.2019.11.020
Deciphering Developmental Disorders Study. (2017). Prevalence and architecture of de novo mutations in developmental disorders. Nature, 542, 433–438. https://doi.org/10.1038/nature21062
Dong, S., Walker, M. F., Carriero, N. J., DiCola, M., Willsey, A. J., Ye, A. Y., Waqar, Z., Gonzalez, L. E., Overton, J. D., Frahm, S., Keaney, J. F., Ill, Tenan, N. A., Dea, J., Mandell, J. D., Bal, V. H., Sullivan, C. A., DiLullo, N. M., Khalil, R. O., Gockley, J., Yuksel, Z., et al. (2014). De novo insertions and deletions of predominantly paternal origin are associated with autism spectrum disorder. Cell Reports, 9, 16–23. https://doi.org/10.1016/j.celrep.2014.08.068
Epi4K Consortium, Epilepsy Phenome/Genome Project, Allen, A. S., Berkovic, S. F., Coosette, P., Delanty, N., Dlugos, D., Eichler, E. E., Epstein, M. P., Glauser, T., Goldstein, D. B., Han, Y., Heiznen, E. L., Hitomi, Y., Howell, K. B., Johnson, M. R., Kuzniecky, R., Lowenstein, D. H., Lu, Y.-F., Madou, M. R. Z., et al. (2013). De novo mutations in epileptic encephalopathies. Nature, 501, 217–221. https://doi.org/10.1038/nature12439
Forrest, M. P., Parnell, E., & Penzes, P. (2018). Dendritic structural plasticity and neuropsychiatric disease. Nature Reviews Neuroscience, 19, 215–234. https://doi.org/10.1038/nrn.2018.16
Fromer, M., Pocklington, A. J., Kavanagh, D. H., Williams, H. J., Dwyer, S., Gornley, P., Georgieva, L., Rees, E., Palta, P., Rudfer, D. M., Carrera, N., Humphreys, I., Johnson, J. S., Roussos, P., Barker, D. D., Banks, E., Milanova, V., Grant, S. H., Gannon, E., Rose, S. A., et al. (2014). De novo mutations in schizophrenia implicate synaptic networks. Nature, 506, 179–184. https://doi.org/10.1038/nature12929
Gilissen, C., Hehir-Kwa, J. Y., Thung, D. T., van de Vorst, M., van Bon, B. W. M., Willemsen, M. H., Kwint, M., Janssen, I. M., Hoischen, A., Schenck, A., Leach, R., Klein, R., Tearel, R., Bo, T., Pfundt, R., Yntema, H. G., de Vries, B. A., Kleefstra, T., Brunner, H. G., Vissers, L. E. L. M., et al. (2014). Genome sequencing identifies major causes of severe intellectual disability. Nature, 511, 344–347. https://doi.org/10.1038/nature13394
Gonzalez-Mantilla, A. J., Moreno-De-Luca, A., Ledbetter, D. H., & Martin, C. L. (2016). A cross-disorder method to identify novel candidate genes for developmental brain disorders. JAMA Psychiatry, 73, 275–283. https://doi.org/10.1001/jamapsychiatry.2015.2692
Grove, J., Ripke, S., Als, T. D., Mattheisen, M., Walters, R. K., Won, H., Pallesen, J., Agerbo, E., Andreassen, O. A., Anney, R., Awasthi, S., Belliveau, R., Bettella, F., Buxbaum, J. D., Bybjerg-Grauholm, J., Bækvad-Hansen, M., Cerrato, F., Chambert, K., Christensen, J. H., Churchhouse, C., et al. (2019). Identification of common genetic risk variants for autism spectrum disorder. *Nature Genetics, 51*, 431–444. https://doi.org/10.1038/s41588-019-0344-8

Guo, H., Li, Y., Shen, L., Wang, T., Jia, X., Liu, L., Xu, T., Ou, M., Hoeckzema, K., Wu, H., Gilleint, M. A., Liu, C., Ni, H., Peng, P., Zhao, R., Zhang, Y., Phosphutkali, C., Stiegmann, A. P. A., Prada, C. E., Hopkin, R. J., et al. (2019). Disruptive variants of CSDE1 associate with autism and interfere with neuronal development and synaptic transmission. *Science Advances, 5*, eaax2166. https://doi.org/10.1126/sciadv.aax2166

Guo, H., Wang, T., Wu, H., Long, M., Coe, B. P., Li, H., Xin, G., Ou, J., Chen, B., Duan, G., Bai, T., Zhao, N., Shen, Y., Li, Y., Wang, Y., Zhang, Y., Baker, C., Liu, Y., Pang, N., Huang, L., et al. (2018). Inherited and multiple de novo mutations in autism/developmental delay risk genes suggest a multifactorial model. *Molecular Autism, 9*, 64. https://doi.org/10.1186/s13229-018-0247-z

Hamdan, F. F., Myers, C. T., Cossette, P., Lemay, P., Spiegelman, D., Laporte, A. D., Nassif, C., Diaio, O., Monlong, J., Cadieux-Dion, M., Dobrzeniecka, S., Meloche, C., Retterer, K., Cho, M. T., Rosenfeld, J. A., Bi, W., Massicotte, C., Miquet, M., Brunga, L., Regan, B. M., et al. (2017). High rate of recurrent de novo mutations in developmental and epileptic encephalopathies. *American Journal of Human Genetics, 101*, 664–685. https://doi.org/10.1016/j.ajhg.2017.09.008

He, X., Sanders, S. J., Liu, L., De Rubeis, S., Lim, E. T., Sutcliffe, J. S., Schellenberg, G. D., Gibbs, R. A., Daly, M. J., Buxbaum, J. D., State, M. W., Devlin, B., & Roeder, K. (2013). Integrated model of de novo and inherited genetic variants yields greater power to identify risk genes. *PLoS Genetics, 9*, e1003671. https://doi.org/10.1371/journal.pgen.1003671

Iossifov, I., O’Roak, B. J., Sanders, S. J., Ronemus, M., Krumm, N., Levy, D., Stessman, H. A., Witherspoon, K. T., Vives, L., Patterson, K. E., Smith, J. D., Paerper, B., Nickerson, D. A., Dea, J., Dong, S., Gonzalez, G. D., Mandell, J. D., Mane, S. M., Murray, M. T., Sullivan, C. A., et al. (2014). The contribution of de novo coding mutations to autism spectrum disorder. *Nature, 515*, 216–221. https://doi.org/10.1038/nature13908

Lago, S. G., Tomaski, J., van Rees, G. F., Ramsey, J. M., Henrichs, F., Cooper, J. D., Broek, J. A., Suarez-Pinilla, P., Rulud, T., Auyeung, B., Mikova, O., Kabusc, N., Arnot, V., Burton-Cohen, S., Crespo-Facorro, B., & Bahn, S. (2018). Exploring the neuropsychiatric spectrum using high-content functional analysis of single-cell signaling networks. *Molecular Psychiatry*. https://doi.org/10.1038/s41386-018-0123-4

Langfelder, P., & Horvath, S. (2008). WGCNA: An R package for weighted correlation network analysis. *BMC Bioinformatics, 9*, 559. https://doi.org/10.1186/1471-2105-9-559

Lelieveld, S. H., Rejinders, M. R. F., Pfundt, R., Yntema, H. G., Kamoni, M., Dean, J., Horton, R., et al. (2018). Quantifying the contribution of recessive variation to developmental disorders. *Science, 362*, 1161–1164. https://doi.org/10.1126/science.aaw7631

Moreno-De-Luca, A., Myers, S. M., Chartman, T. D., Moreno-De-Luca, D., Evans, D. W., & Ledbetter, D. H. (2013). Developmental brain dysfunction: Revival and expansion of old concepts based on new genetic evidence. *Lancet Neurology, 12*, 406–414. https://doi.org/10.1016/S1474-4422(13)70011-5

Nguyen, H. T., Bryois, J., Kim, A., Dobbyn, A., Hucks, L. M., Munoz-Manchado, A. B., Ruderfer, D. M., Genovese, G., Fromer, M., Xu, X., Pinto, D., Linnarsson, S., Verhage, M., Smit, A. B., Hjerling-Leffler, J., Buxbaum, J. D., Hultman, C., Sklar, P., Purcell, S. M., Lage, K., et al. (2017). Integrated Bayesian analysis of rare exonic variants to identify risk genes for schizophrenia and neurodevelopmental disorders. *Genome Medicine, 9*, 114. https://doi.org/10.1186/s13073-017-0497-y

Parikh, S. N., Luo, R., Zhang, A., Won, H., Lowe, J. K., Chandran, V., Horvath, S., & Geschwind, D. H. (2013). Integrative functional genomic analyses implicate specific molecular pathways and circuits in autism. *Cell, 155*, 1008–1021. https://doi.org/10.1016/j.cell.2013.10.031

Petrovski, S., Wang, Q., Heinz, E. L., Allen, A. S., & Goldstein, D. B. (2013). Genic intolerance to functional variation and the interpretation of personal genomes. *PLoS Genetics, 9*, e1003709. https://doi.org/10.1371/journal.pgen.1003709
Plana-Ripoll, O., Pedersen, C. B., Holtz, Y., Benros, M. E., Dalsgaard, s., de Jonge, P., Fan, C. C., Degenhardt, L., Ganna, A., Greve, A. N., Gunn, J., Iburg, K. M., Kessing, L. V., Lee, B. K., Lim, C. C. W., Mors, O., Nordentoft, M., Prior, A., Roest, A. M., Saha, S., et al. (2019). Exploring comorbidity within mental disorders among a Danish national population. *JAMA Psychiatry*. https://doi.org/10.1001/jamapsychiatry.2018.3656

Polderman, T. J. C., Benyamin, B., de Leeuw, C. A., Sullivan, P. F., van Bochove, A., Visscher, P. M., & Posthuma, D. (2015). Meta-analysis of the heritability of human traits based on fifty years of twin studies. *Nature Genetics*, 47, 702–709. https://doi.org/10.1038/ng.3285

Ripke, S., O'Dushlaine, C., Chamberl, K., Moran, J. L., Kähler, A. K., Akterin, S., Bergen, S. E., Collins, A. L., Crowley, J. J., Fromer, M., Kim, Y., Lee, S. H., Magnusson, P. K. E., Sanchez, N., Stahl, E. A., Williams, S., Wray, N. R., Xie, K., Bettella, F., Borglam, A. D., et al. (2013). Genome-wide association analysis identifies 13 new risk loci for schizophrenia. *Nature Genetics*, 45, 1150–1159. https://doi.org/10.1038/ng.2742

Robertson, J., Hatton, C., Emerson, E., & Baines, S. (2015). Prevalence of epilepsy among people with intellectual disabilities: A systematic review. *Seizure*, 29, 46–62. https://doi.org/10.1016/j.seizure.2015.03.016

Satterstrom, F. K., Kosmicki, J. A., Wang, J., Breen, M. S., De Rubeis, S., An, J.-Y., Peng, M., Collins, R., Grove, J., Klei, L., Stevens, C., Reichert, J., Mulhern, M. S., Artomov, M., Gerges, S., Sheppard, B., Xu, X., Bhaduri, A., Norman, U., Brand, Hs., et al. (2020). Large-scale exome sequencing study implicates both developmental and functional changes in the neurobiology of autism. *Cell*, 180, 568-584.e23. https://doi.org/10.1016/j.cell.2019.12.036

Schork, A. J., Won, H., Appadurai, V., Nudel, R., Gandal, M., Delaneeu, O., Revesbech Christiansen, M., Hougaard, D. M., Bækked-Hansen, M., Bybjerg-Grauholm, J., Pedersen, M. G., Agerbo, E., Pedersen, C. B., Neale, B. M., Daly, M. J., Wray, N. R., Nordentoft, M., Mors, O., Børslum, A. D., Mortensen, P. B., et al. (2019). A genome-wide association study of shared risk across psychiatric disorders implicates gene regulation during fetal neurodevelopment. *Nature Neuroscience*. https://doi.org/10.1038/s41593-018-0320-0

Shi, Y.-W., Zhang, Q., Cai, K., Poliquin, S., Shen, W., Winters, N., Yi, Y.-H., Wang, J., Hu, N., Macdonald, R. L., Liao, W.-P., & Kang, J.-Q. (2019). Synaptic clustering differences due to different GABRB3 mutations cause variable epilepsy syndromes. *Brain*, 142, 3028–3044. https://doi.org/10.1093/brain/awz250

Shohat, S., Ben-David, E., & Shifman, S. (2017). Varying intolerance to Tillotson, R., Selfridge, J., Koerner, M. V., Gadalla, K. K. E., Guy, J., & De Sousa, D. (2017). Radically truncated McCP2 rescues Rett syndrome-like neurological defects. *Nature*, 550, 398–401. https://doi.org/10.1038/nature24058

van Bon, B. W. M., Hoe, C. P., Bernier, R., Green, C., Gerds, J., Witherspoon, K., Kilefstra, T., Willemsen, M. H., Kumar, R., Bosco, P., Fichera, M., Li, D., Amaral, D., Cristofoli, F., Peeters, H., Haan, E., Romano, C., Mefford, H. C., Scheffer, I., Geicz, J., et al. (2016). Disruptive de novo mutations of DYRK1A lead to a syndromic form of autism and ID. *Molecular Psychiatry*, 21, 126–132. https://doi.org/10.1038/mp.2015.5

Wang, K., Li, M., & Hakonarson, H. (2010). ANNOVAR: Functional annotation of genetic variants from high-throughput sequencing data. *Nucleic Acids Research*, 38, e164. https://doi.org/10.1093/nar/gkq603

Wang, L., Zhang, Y., Li, K., Wang, Z., Wang, X., Li, B., Zhao, G., Fang, Z., Ling, Z., Luo, T., Xia, L., Li, Y., Guo, H., Hu, Z., Li, J., Sun, Z., & Xia, K. (2020). Functional relationships between recessive inherited genes and genes with de novo variants in autism spectrum disorder. *Molecular Autism*, 11, 75. https://doi.org/10.1186/s13229-020-00382-x

Wang, T., Guo, H., Xiong, B., Stessman, H. A. F., Wu, H., Coe, B. P., Turner, T. N., Liu, Y., Zhao, W., Hoekzema, K., Lives, L., Xia, L., Tang, M., Ou, J., Chen, B., Shen, Y., Xun, G., Long, M., Lin, J., Kronenberg, Z. N., et al. (2016). De novo generic mutations among a Chinese autism spectrum disorder cohort. *Nature Communications*, 7, 13316. https://doi.org/10.1038/ncomms13316

Williams, A. J., Morris, M. T., Wang, S., Willsey, H. R., Sun, N., Teerlinkori, N., Baum, T. B., Cagney, G., Bender, K. J., Desai, T. A., Srivastava, D., Davis, G. W., Doudna, J., Chang, E., Suhal, V., Lowenstein, D. H., Li, H., Agard, D., Keiser, M. J., Shoichet, B., et al. (2018). The Psychiatric Cell Map Initiative: A convergent systems biological approach to illuminating key molecular pathways in neuropsychiatric disorders. *Cell*, 174, 505–520. https://doi.org/10.1016/j.cell.2018.06.016

Willsey, A. J., Sanders, S. J., Li, M., Dong, S., Tebbenkamp, A. T., Muhle, R. A., Reilly, S. K., Lin, L., Furtuzinhos, S., Miller, J. A., Murtha, M. T., Bichsel, C., Niu, W., Cotney, J., Ercan-Sencicke, A. G., Gockley, J., Gupta, A. R., Han, W., He, X., Hoffman, E. J., et al. (2013). Coexpression networks implicate human midfetal deep cortical projection neurons in the pathogenesis of autism. *Cell*, 155, 997–1007. https://doi.org/10.1016/j.cell.2013.10.020

Wolff, M., Johannesen, K. M., Hedrich, U. B. S., Masnada, S., Rubboli, G., Gardella, E., Lesca, G., Ville, D., Milh, M., Villard, L., Afenjar, A., Chantot-Bastarda, S., Mignot, C., Lardenois, C., Nava, C., Schwarz, N., Gérard, M., Perrin, L., Doummar, D., Auvin, S., et al. (2017). Genetic and phenotypic heterogeneity suggest therapeutic implications in SCN2A-related disorders. *Brain*, 140, 1316–1336. https://doi.org/10.1093/brain/awx054

XiangWei, W., Kanna, V., Xu, Y., Kosobucki, G. J., Schullien, A. J., Kusumoto, H., El Ackhar, C. M., Bhattacharya, S., Lesca, G., Nguyen, S., Helbig, K. L., Cuisset, J.-M., Fenger, C. D., Marjanovic, D., Schuler, E., Wu, Y., Bao, X., Zhang, Y., Dirkx, N., Schoonjans, A.-S., et al. (2019). Heterogeneous clinical and functional features of GRIN2D-related developmental and epileptic encephalopathy. *Brain*, 142, 3009–3027. https://doi.org/10.1093/brain/awz232

Zhao, G., Li, K., Li, B., Wang, Z., Fang, Z., Wang, X., Zhang, Y., Luo, T., Zhou, Q., Wang, L., Xie, Y., Wang, Y., Chen, Q., Xia, L., Tang, Y., Tang, B., Xia, K., & Li, J. (2019). Gene4Denovo: An integrated database and analytic platform for de novo mutations in humans. *Nucleic Acids Research*. https://doi.org/10.1093/nar/gkz923

Zhou, Y., Zhou, B., Pache, L., Chang, M., Khodabakhshi, A. H., Tana-seichuk, O., Benner, C., & Chanda, S. K. (2019). Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. *Nature Communications*, 10, 1523. https://doi.org/10.1038/s41467-019-09234-6

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.